№ files_lp_4_process_3_139361
File format: docx
Character count: 3292
File size: 23 KB
Inpatient guidance document detailing hospitalization expectations, care procedures, infection control, dietary requirements, medical monitoring, therapy routines, and discharge planning for cystic fibrosis patients.
Year:
2026
Location:
University of Cincinnati Hospital, 8 East Unit
Subject:
Cystic Fibrosis inpatient care and hospital protocols
Document Type:
Patient guidance / hospital procedure
Institution:
UC Hospital Pulmonary Consult Service
Author:
CF Nurse Practitioner Angela Oder
Target Audience:
CF patients and their families
Admission Requirements:
Direct or scheduled CF admissions
Infection Control:
Droplet & Contact isolation, personal protective equipment required
Dietary Guidelines:
High calorie diet (3000 cal/day), extended menu for CF patients
Medical Monitoring:
Vital signs every 8 hours, weight 2–4 times per week, glucose monitoring as needed
Therapy and Exercise:
4 respiratory therapy sessions/day, encouraged physical activity, home IV setup guidance upon discharge
Follow-up:
Appointment within 2 weeks post-discharge
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2019
Region / City:
Hawaii
Topic:
Health, Involuntary Hospitalization
Document Type:
Meeting Minutes
Organization:
Hawaii State Capitol
Author:
Task Force Members
Target Audience:
Health Professionals, Task Force Members, Policymakers
Period of Action:
September 17, 2019 - October 25, 2019
Approval Date:
September 17, 2019
Date of Changes:
October 4, 2019
Author:
Annette McCollough
Document Type:
Medical case studies and clinical records
Facility:
Oakdale Nursing Home
Insurance:
Medicare
Patient Names:
Cora Wilkinson; Sarah White
Dates of Service:
January 6–15, 2014
Clinical Settings:
Skilled nursing facility; Inpatient hospital oncology unit
Primary Diagnoses:
Cellulitis of left foot; Neutropenic sepsis; Non-Hodgkin’s lymphoma; Pancytopenia; Hypertension
Treatments:
IV antibiotics; Platelet and blood transfusions; Neupogen injections; Reverse isolation
Medications Mentioned:
Insulin 70/30; Vancomycin; Fortaz; Gentamicin; Cipro; Floxin; Mycostatic; Penicillin; Benadryl; Steroids
Disposition:
Discharge to home with outpatient follow-up
Year:
1953
Region / city:
Mississippi
Subject:
Mental Health / History
Document type:
Manuscript
Institution:
Whitfield
Author:
Fred Chaney
Target audience:
General public
Period of validity:
1953
Approval date:
1953
Date of changes:
1957
Avoiding a Serious RSV Infection and Hospitalization of Your Baby (RSV Season from October 1st 2025)
Country:
Belgium
Topic:
Prevention of RSV infection and bronchiolitis in infants
Document type:
Public health information leaflet
Target audience:
Parents of newborns and infants
Medical focus:
RSV (Respiratory Syncytial Virus) and bronchiolitis
Preventive product:
Nirsevimab (Beyfortus®)
Related vaccine:
Abrysvo®
Institutions mentioned:
Kind&Gezin; ONE in Wallonia
Period concerned:
RSV season (autumn and winter months)
Start date of measure:
October 1st 2025
Reimbursement conditions:
Social insurance with doctor’s prescription; preferential reimbursement available
Administration setting:
Maternity ward or shortly after birth
Geographical scope:
Belgium
Year:
2021
Region / City:
Massachusetts
Topic:
COVID-19 Vaccine Breakthrough Cases
Document Type:
Memorandum
Organization:
Massachusetts Department of Public Health
Author:
Catherine M. Brown, DVM, MSc, MPH; Larry Madoff, MD
Target Audience:
Hospital-based Providers and Infection Preventionists
Date of Approval:
May 25, 2021
Date of Changes:
None
Context:
This document provides guidelines for reporting breakthrough COVID-19 cases that result in hospitalization or death in fully vaccinated individuals in Massachusetts.
Year:
Not specified
Region / Location:
Not specified
Field:
Neurobiology of swallowing, dysphagia management, pediatric feeding therapy
Document Type:
Clinical case study and therapy planning worksheet
Institution / Setting:
Clinical rehabilitation / feeding therapy context
Author:
Not specified
Patient Age:
18 months
Patient Condition:
Developmental delay following brain tumor resection with prolonged hospitalization and intubation
Clinical History:
Two-month hospital stay including two weeks of intubation; discharged with thickened liquids, soft and bite-sized diet, and nasogastric tube feeding
Primary Clinical Issues:
Aspiration of thin liquids, reduced oral intake, impaired chewing, oral motor weakness, attention and feeding behavior difficulties
Diagnostic Assessment:
Modified Barium Swallow Study (MBSS) / VFSS
Feeding Support:
NG tube with overnight continuous formula feeding
Target Areas:
Mealtime behavior, hunger regulation, oral sensory awareness, tongue lateralization, jaw strengthening, attention, self-feeding skills, straw drinking
Therapeutic Approaches:
Environmental adaptation, parent coaching, oral motor exercises, sensory stimulation, task-specific chewing practice, feeding routine structuring
Diet Level at Discharge:
Slightly thick liquids and soft & bite-sized solids
Key Symptoms:
Slow eating, distraction during meals, food pocketing, coughing with oral hygiene, aspiration of thin liquids, weak lip seal and intra-oral pressure
Year:
2006-2015
Region / city:
United Kingdom
Theme:
Environmental health, cardiovascular disease, noise exposure
Document type:
Research paper
Organization / institution:
Imperial College London, University of Leicester
Authors:
Garyfallos Konstantinoudis, Glory Atilola, Calvin Jephcote, Kathryn Adams, John Gulliver, Paul Elliott, Anna L Hansell, Marta Blangiardo
Target audience:
Researchers, public health professionals, policy makers
Period of validity:
2006-2015
Approval date:
Not specified
Date of changes:
Not specified
Year:
2014
Region / city:
Qatar
Topic:
Medical Research
Document Type:
Research Article
Author(s):
Atqah AbdulWahab, Saad J Taj-Aldeen, Emad Ibrahim, Shaikha H Abdulla, Ramees Muhammed, Irshad Ahmed, Yasmine Abdeen, Omnia Sadek, Marawan Abu-Madi
Target Audience:
Medical professionals, researchers in infectious diseases
Date of approval:
2014
Note:
Contextual description
Year:
2020
Region / City:
Zhejiang Province, China
Field:
Gynecology
Document Type:
Case Report
Organization / Institution:
Zhejiang University School of Medicine, Women’s Hospital
Authors:
Zhou Y, Zheng-Yun Chen, Xin-Mei Zhang
Target Audience:
Medical professionals, researchers in gynecology
Period of validity:
N/A
Date of approval:
N/A
Date of changes:
N/A
Date received:
September 2, 2019
Date revised:
November 28, 2019
Date accepted:
December 13, 2019
Date published online:
January 6, 2020
Keywords:
Cystic adenomyosis, Dysmenorrhea, Levonorgestrel containing intrauterine device, Myomectomy, Case report
URL:
https://www.wjgnet.com/2307-8960/full/v8/i1/188.htm
DOI:
https://dx.doi.org/10.12998/wjcc.v8.i1.188
Context:
This is a medical case report detailing a rare instance of giant exophytic cystic adenomyosis with a levonorgestrel-containing intrauterine device out of the uterine cavity following uterine myomectomy.
Authors:
Noelia Rodriguez Mier; Senne Cuyx; Kris De Boeck; Marijke Proesmans; Mieke Boon; Lieven Dupont; Kaline Arnauts; Elke De Wachter; Stephanie Van Biervliet; Monique Lequesne; Vicky Nowé; Hedwige Boboli; Anabela Santo Ramalho; François Vermeulen; on behalf of the Belgian Organoid Project
Affiliations:
KU Leuven; University Hospital Leuven; University Hospital Brussels; Ghent University Hospital; Antwerp University Hospital; GZA Hospital; CHR Citadelle
Country:
Belgium
Research field:
Cystic fibrosis; CFTR modulators; organoid research; personalized medicine
Study population:
60 people with cystic fibrosis homozygous for F508del
Genetic focus:
F508del CFTR mutation (homozygous)
Interventions studied:
Elexacaftor/tezacaftor/ivacaftor; Tezacaftor/ivacaftor
Methods:
Patient-derived intestinal organoids from rectal biopsies; forskolin-induced swelling assay; comparison with clinical outcomes
Clinical outcomes assessed:
Lung function; sweat chloride levels; body weight; pulmonary exacerbations
Type of document:
Scientific research article
Source:
PubMed
DOI / Identifier:
40883119
Year:
2023
Region / City:
Royal Devon & Exeter Hospital, Wonford, UK
Topic:
Healthcare, Physiotherapy
Document Type:
Job Description
Organization / Institution:
Royal Devon University Healthcare NHS Foundation Trust
Author:
N/A
Target Audience:
Healthcare professionals, physiotherapists
Period of Validity:
N/A
Approval Date:
N/A
Amendment Date:
N/A
Year:
2025
Organization:
Alder Hey Children’s NHS Foundation Trust
Department:
Department of Respiratory Medicine
Document type:
Patient information leaflet
Target audience:
Patients, parents and carers of children with cystic fibrosis
Topic:
Genetics of cystic fibrosis, carrier testing, reproductive options
Review date:
March 2025
Contact:
Tel: 0151 228 4811, www.alderhey.nhs.uk
Location:
Liverpool, United Kingdom
Year:
2016
Author:
Tamia Jackson
Date:
March 11, 2016
Period/Class:
5th period
Topic:
Cystic Fibrosis
Document Type:
Educational overview
Intended Audience:
Students
Key Subjects:
Genetic causes, airway clearance, inhaled medications, nutrition, fitness, CFTR modulators, lung transplantation
Related Conditions:
Fibrocystic Disease of the pancreas, Mucoviscidosis
Medical Note:
There is no cure for Cystic Fibrosis
Year:
Not specified
Region / Area:
Europe
Subject:
Post-authorisation safety and efficacy studies in cystic fibrosis registries
Document Type:
Application form
Organization:
European Cystic Fibrosis Society Patient Registry (ECFSPR)
Related Organization:
European Medicines Agency (EMA)
Applicant Type:
Marketing Authorisation Holder
Purpose:
Submission of requests for registry data for PASS / PAES studies
Required Attachments:
Study protocol; Statistical analysis plan
Submission Method:
Email submission to [email protected]
Key Sections:
Applicant details; Study information; Cohort definition; Statistical methods; Data requirements
Population Scope:
Patients included in the European Cystic Fibrosis Society Patient Registry
Historical Data Availability:
2008–2023
Fee Structure:
€5,000 handling; €25,000 review and feasibility assessment; €5,000 application modification
Governance Note:
Individual country applications outside ECFSPR governance may apply separate fees
Year:
2023
Region / City:
United Kingdom
Theme:
Health-related quality of life, Cystic fibrosis
Document Type:
Research Article
Author:
Rana Altabee, Siobhan B. Carr, Jaince Abbott, Rory Cameron, Daniel Office, Nicholas J. Simmonds, Jennifer A. Whitty, David Turner, Garry Barton
Target Audience:
Researchers, healthcare professionals, policy makers
Period of Study:
July 2020 – March 2021
Approval Date:
2023
Date of Changes:
None
Year:
2014
Region / city:
Qatar
Topic:
Medical Research
Document Type:
Research Article
Author(s):
Atqah AbdulWahab, Saad J Taj-Aldeen, Emad Ibrahim, Shaikha H Abdulla, Ramees Muhammed, Irshad Ahmed, Yasmine Abdeen, Omnia Sadek, Marawan Abu-Madi
Target Audience:
Medical professionals, researchers in infectious diseases
Date of approval:
2014
Note:
Contextual description
Year:
2023
Region / City:
Wuhan, China
Topic:
Gene expression, liver fibrosis, HCC
Document Type:
Research Article
Organization / Institution:
Zhongnan Hospital of Wuhan University, Wuhan University
Author:
Not specified
Target Audience:
Researchers, clinicians, medical professionals
Duration:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Note:
Context
Year:
2010-2024
Region / city:
Asia-Pacific
Subject:
Hepatology
Document Type:
Clinical Practice Guidelines
Organization / Institution:
Asian Pacific Association for the Study of the Liver (APASL)
Author:
APASL
Target Audience:
Healthcare professionals
Period of validity:
2010-2024
Date of approval:
2010
Date of revisions:
2024
Context:
Collection of clinical practice guidelines and consensus statements issued by the Asian Pacific Association for the Study of the Liver on various hepatological conditions, including hepatocellular carcinoma, hepatitis B and C, liver transplantation, and metabolic diseases.
Authors:
Noelia Rodriguez Mier; Senne Cuyx; Kris De Boeck; Marijke Proesmans; Mieke Boon; Lieven Dupont; Kaline Arnauts; Elke De Wachter; Stephanie Van Biervliet; Monique Lequesne; Vicky Nowé; Hedwige Boboli; Anabela Santo Ramalho; François Vermeulen; on behalf of the Belgian Organoid Project
Affiliations:
KU Leuven; University Hospital Leuven; University Hospital Brussels; Ghent University Hospital; Antwerp University Hospital; GZA Hospital; CHR Citadelle
Country:
Belgium
Research field:
Cystic fibrosis; CFTR modulators; organoid research; personalized medicine
Study population:
60 people with cystic fibrosis homozygous for F508del
Genetic focus:
F508del CFTR mutation (homozygous)
Interventions studied:
Elexacaftor/tezacaftor/ivacaftor; Tezacaftor/ivacaftor
Methods:
Patient-derived intestinal organoids from rectal biopsies; forskolin-induced swelling assay; comparison with clinical outcomes
Clinical outcomes assessed:
Lung function; sweat chloride levels; body weight; pulmonary exacerbations
Type of document:
Scientific research article
Source:
PubMed
DOI / Identifier:
40883119
Medicine:
Pirfenidone 267 mg capsule
Brand name:
Esbriet®
Manufacturer:
Roche Products Pty Ltd
Quantity:
270 capsules
Maximum quantity:
1
Number of repeats:
5
Program:
Section 100 – Highly Specialised Drugs Program
Schedule:
General Schedule (Code GE)
Condition:
Idiopathic pulmonary fibrosis
Treatment phases:
Initial treatment; Continuing treatment; Initial PBS-subsidised treatment (grandfather patient)
Restriction level:
Restricted benefit – Authority Required
Authority method:
In Writing; Telephone; Emergency; Electronic; Streamlined
Prescriber requirement:
Respiratory physician or specialist physician experienced in idiopathic pulmonary fibrosis
Population criteria:
Patients aged 40 years or older
Clinical criteria (initial):
Confirmed diagnosis of idiopathic pulmonary fibrosis supported by HRCT with or without surgical lung biopsy; FVC ≥ 50%; DLCO ≥ 30%
Clinical criteria (continuing):
Prior PBS-subsidised treatment with pirfenidone
Administrative authority:
Department of Human Services, Australia
Application requirement:
Completed authority prescription form and IPF Initial PBS authority application form with supporting diagnostic documentation
Geographical reference:
Hobart, TAS 7001, Australia